Recently, the Nansha District of Guangzhou held a conference to promote the high-quality development of the biopharmaceutical industry. The Nansha Development Zone Management Committee and the Nansha District People's Government issued the "Opinions on Accelerating the High quality Development of the biopharmaceutical Industry in Nansha, Guangzhou" and the "Measures for Supporting the High quality Development of the biopharmaceutical Industry in Nansha, Guangzhou" at the conference.

High quality development

Strive to exceed 50 billion yuan in industrial scale by 2026

The "Opinions on High Quality Development of Biomedical Industry" is a systematic plan and deployment arrangement for the biopharmaceutical industry in Nansha in the coming years, involving four major aspects: development goals, key tracks, spatial layout, and implementation measures.

One is to focus on building an influential international medical and health highland.

Nansha firmly grasps the national reform pilot tasks and provincial and municipal support policies, adheres to the equal emphasis on research and development, manufacturing, and services, focuses on drugs, medical devices, medical services, and other fields, and is committed to building a policy support system for the entire biopharmaceutical industry chain that covers research and development, clinical practice, manufacturing, factors, and ecology.

The goal is to strive to gather more than 1000 enterprises and achieve an industrial scale of over 50 billion yuan by 2026; The newly added industrial carriers have reached 1 million square meters. To build Nansha into a "Greater Bay Area Pharmaceutical Port" and an influential international medical service highland.

The second is to focus on key sub sectors and make every effort to build a "4+2+2" industrial system.

"4" refers to four high-end pharmaceutical equipment industry segments, including innovative drugs, new vaccines, high-value consumables, and in vitro diagnostics; The first "2" refers to two cutting-edge technological innovation poles, namely cell and gene therapy and neuroscience; The second "2" refers to creating two well-known industrial landmark business cards with Nansha characteristics, namely ophthalmology and anti-tumor.

The third is to accelerate the construction of the industrial spatial layout of "one city, three valleys, and six parks".

High standard planning and construction of an international medical and health city (one city); We will make every effort to promote the construction of "Biovalley, the Pearl River Innovation Valley, Health Valley" and other clusters (three valleys); Accelerate the construction of professional parks including Guangdong Medical Valley, Zhongda Pharmaceutical Valley, Fudan Innovation Park, Hengli Biomedical Industry Park, Life and Health Industry Park, and Guangzhou Industry Investment Digital Economy and Life Science Industry Park (six parks).

The fourth is to implement the "Six Major Projects" campaign.

Focusing on the current shortcomings in the development of the biopharmaceutical industry in Nansha, we will systematically implement six major projects, including platform construction, enterprise recruitment and training, spatial improvement, policy support, financial empowerment, and industrial cooperation. We will strengthen and supplement the supply chain, attract strong talents, and use the greatest courage and determination to promote the rational and efficient allocation of resources.

Nine Articles of Biomedical Medicine

The maximum reward can reach 100 million yuan

A sound top-level design requires a comprehensive policy system to provide support. Nansha released the "Supporting Measures for Promoting High Quality Development of the Biomedical Industry" (referred to as the "Nine Measures for Biomedical Industry") at the meeting. If the "Opinions" are the "Outline" for the development of biopharmaceuticals in Nansha, then the "Supporting Measures" are the "Objectives", and Nansha will systematically promote the high-quality development of the biopharmaceutical industry.

After the State Council issued the "Nansha Plan" in June 2022, a series of policies supporting Nansha were successively introduced by the country, provinces, and cities, ushering in a "spring" for the development of the biopharmaceutical industry in Nansha. Nansha has extensively listened to industry voices, conducted policy consultations, benchmarking against advanced regions, and based on the actual situation in Nansha, proposed the "Nine Articles of Biomedical Products" tailored to local conditions:

The first item is the reward for the application of cell and gene technology.

Nansha responds to the national policy call and further encourages bold innovation, experimentation, and distinctive features in cell and gene therapy. Specifically, it can be summarized as "two supports and one encouragement": supporting cell and gene therapy companies to carry out clinical applications of restricted cell transplantation therapy technologies; Support Hong Kong and Macau enterprises in conducting medical research beyond human stem cell and gene diagnosis and treatment. At the same time, foreign enterprises are encouraged to develop and apply genetic diagnosis and treatment technologies, and rewards will be given at a rate of 2% of their foreign investment amount.

The second item is the reward for leading enterprises.

For top enterprises investing more than 200 million yuan in the construction of production and research and development bases in Nansha, a reward of 10% of the fixed investment will be given, with a maximum of 100 million yuan.

The third article is the reward for the construction of clean production workshops.

For those with an area exceeding 1000 square meters and a fixed investment of over 5 million yuan, a reward of 25% and 15% will be given for fixed investment based on the purchase or rental of the site.

The fourth article is clinical trial rewards.

One is to provide advanced support. In order to enhance the sense of achievement of the enterprise, once the enterprise obtains the clinical trial license, it can receive a reward of 2 million yuan for Class 1 and 1 million yuan for Class 2 drugs; The second is to encourage industrialization. On the basis of the subsidy and support policies for enterprise clinical trial research and development in Guangzhou, Nansha District will provide additional rewards of 15 million and 8 million for Class 1 and Class 2 drugs that have completed Phase III clinical trials, respectively.

The fifth article is the reward for registration certificates.

Nansha will provide a reward of 3 million yuan for the registration certificate of Class III medical devices. Special attention has been paid to innovative medical devices, and the registration certificates for the second and third types of innovative medical devices will be rewarded with 1 million and 5 million respectively.

Article 6 is a rental subsidy for research and development production sites.

The purpose is to help enterprises with certain R&D investment strength and market development ability reduce operating costs, and to subsidize 50% of rent for three consecutive years.

The seventh article is a reward for new quality growth.

Encourage biopharmaceutical enterprises to become the "main force" of new quality productivity, and provide a reward of 100000 yuan for every 20 million new industrial output, with no upper limit.

Article 8 is the CRO/CMO/CDMO enterprise reward.

Accelerate the construction of the biopharmaceutical industry ecosystem, assist the industrialization process through platform enterprises, and reward CRO/CMO/CDMO enterprises with 5% of the contract settlement amount.

Article 9 is the reward for scenario application.

In response to the relatively concentrated high-end medical and scientific research institutions in Nansha District, efforts are being made to further stimulate the interactive vitality between medical and scientific research institutions and biopharmaceutical enterprises in the area, fully unleashing market scenarios. On the one hand, reward institutions with 1% of the contract settlement amount; On the other hand, institutions providing clinical trial services for new drugs will be rewarded at a rate of 5% of their service revenue.